Publications by authors named "J L Bauman"
Article Synopsis
- * An analysis of 610 mPC patients revealed that those who had palliative care consultations were significantly less likely to undergo chemotherapy close to death, more likely to have do-not-resuscitate (DNR) orders, and more often referred to hospice care.
- * Despite these differences in care approach, there was no significant change in overall survival rates for patients who received palliative care compared to those who didn’t, indicating that integrating palliative care mainly affects the quality of care at the end
Article Synopsis
- Aggressive end-of-life (EOL) care for cancer patients often results in more hospitalizations and a poorer quality of death, while effective goals of care (GOC) discussions can lead to fewer hospitalizations and increased hospice use.* -
- A study at an academic cancer center found that less than half of patients had documented GOC discussions, despite those discussions being linked to higher rates of hospice enrollment and lower hospitalizations.* -
- It’s suggested that hematology-oncology fellowship programs should enhance communication skills training to improve the quality of GOC documentation and EOL care for patients.*
Background: Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. We aimed to assess whether radiotherapy with concurrent and adjuvant durvalumab would improve outcomes compared with radiotherapy with cetuximab.
Methods: NRG-HN004 was designed as an open-label, multicentre, parallel-group, randomised, phase 2/3 trial with safety lead-in conducted at 89 academic and community medical centres in North America.
Purpose: This phase Ib trial evaluated fibroblast activation protein-α-targeted IL2 variant (FAP-IL2v), a novel immunocytokine engineered to minimize CD25-mediated toxicities, in combination with cetuximab, in patients with recurrent, unresectable, or metastatic head and neck squamous cell carcinoma (HNSCC).
Patients And Methods: Patients received FAP-IL2v either on a continuous weekly (QW) schedule or QW for 4 weeks and then every 2 weeks (Q2W). Cetuximab was dosed at QW or Q2W schedules.